This litigation has concluded and we are proud to report that our clients' claims have been successfully resolved. The amounts of all individual client recoveries are confidential, both by settlement agreement and by attorney-client privilege. MLG is no longer accepting cases involving this product.
Xarelto® is an anti-blood-clotting drug that was first approved by the FDA to prevent Deep Vein Thrombosis (DVT) in patients having knee or hip replacement surgery, and then for treatment of patients with Atrial Fibrillation (A-Fib) not caused by cardiac valve deficiencies. Potential consequences of blood clots caused by DVT and A-Fib are pulmonary embolism and ischemic stroke. Anti-clotting medications are used to prevent such clots from forming and causing potentially fatal consequences.
Unlike the traditional anti-clotting medication Warfarin (Coumadin®), there is no effective anti-dote to reverse the anti-coagulative effects of Xarelto®. Therefore, unlike Warfarin (Coumadin®), if unintended bleeding occurs, there is no emergency treatment that will readily reverse the anti-coagulation and thereby stop the bleeding. There have been numerous reports of bleeding injuries, most notably hemorrhages, associated with the use of Xarelto®. Learn more about bleeding injuries and other risks associated with Xarelto® here.
This litigation has concluded and we are proud to report that our clients' claims have been successfully resolved. The amounts of all individual client recoveries are confidential, both by settlement agreement and by attorney-client privilege. MLG is no longer accepting cases involving this product.